L3VLUP
ProSign in

JANX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

JANXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • JANX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterJANXLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 20211 holders, $8.3m24 holders, $27.8bn
Q3 20211 holders, $6.5m31 holders, $29.9bn
Q4 20211 holders, $5.5m31 holders, $34.7bn
Q1 20221 holders, $4.0m24 holders, $35.3bn
Q2 20221 holders, $3.5m33 holders, $42.7bn
Q3 20221 holders, $5.4m31 holders, $43.4bn
Q4 20221 holders, $6.7m31 holders, $46.6bn
Q1 20231 holders, $1.7m33 holders, $44.3bn
Q2 20231 holders, $1.6m37 holders, $59.6bn
Q3 20231 holders, $864k44 holders, $67.6bn
Q4 2023none listed holders, n.a.45 holders, $73.6bn
Q1 20243 holders, $76m41 holders, $95.3bn
Q2 20243 holders, $98m43 holders, $110bn
Q3 20245 holders, $218m45 holders, $107bn
Q4 20248 holders, $850m46 holders, $93.9bn
Q1 20253 holders, $174m42 holders, $98.4bn
Q2 20254 holders, $182m43 holders, $93.2bn
Q3 20253 holders, $182m39 holders, $86.7bn
Q4 20252 holders, $88m41 holders, $123bn
Q1 20261 holders, $58m39 holders, $106bn
Q2 20261 holders, $1.4m44 holders, $132bn
JANX

Janux Therapeutics Inc

Holders
4
Reported value
$182m
Buyers
1
Sellers
2

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$93.2bn
Buyers
25
Sellers
22

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 44 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only JANX (1)

Farallon Capital Management LLC

Only LLY (40)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, and 15 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →